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Abstract
A major problem with current anti-depressant therapy is that it takes on average 6–7 weeks for
remission. Since desensitization of serotonin (5-HT)1A receptor signaling contributes to the anti-
depressive response, acceleration of the desensitization may reduce this delay in response to
antidepressants. The purpose of the present study was to test the hypothesis that estradiol
accelerates fluoxetine-induced desensitization of 5-HT1A receptor signaling in the paraventricular
nucleus of the hypothalamus (PVN) of rats, via alterations in components of the 5-HT1A receptor
signaling pathway. Ovariectomized rats were injected with estradiol and/or fluoxetine, then
adrenocorticotropic hormone (ACTH) and oxytocin responses to a 5-HT1A receptor agonist (+)8-
hydroxy-2-dipropylaminotetralin (8-OH-DPAT) were examined to assess the function of 5-HT1A
receptors in the PVN. Treatment with estradiol for either 2 or 7 days or fluoxetine for 2 days
produced at most a partial desensitization of 5-HT1A receptor signaling, whereas 7 days of
fluoxetine produced full desensitization. Combined treatment with estradiol and fluoxetine for 2
days produced nearly a full desensitization, demonstrating an accelerated response compared to
either treatment alone. With two days of combined treatments, estradiol prevented the fluoxetine-
induced increase in 5-HT1A receptor protein, which could contribute to the more rapid to the
desensitization. Furthermore, EB treatment for 2 days decreased the abundance of the 35 kD Gαz
protein which could contribute to the desensitization response. We found two isoforms of Gαz
proteins with molecular mass of 35 and 33 kD, which differentially distributed in the detergent
resistant microdomain (DRM) and in Triton X-100 soluble membrane region, respectively. The 35
kD Gαz proteins in the DRM can be sumoylated by SUMO1. Stimulation of 5-HT1A receptors
with 8-OH-DPAT increases the sumoylation of Gαz proteins and reduces the 33 kD Gαz proteins,
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suggesting that these responses may be related to the desensitization of 5-HT1A receptors.
Treatment with estradiol for 2 days also reduced the levels of the G-protein coupled estrogen
receptor GPR30, possibly limiting to the ability of estradiol to produce only a partial
desensitization response. These data provide evidence that estradiol may be effective as a short-
term adjuvant to SSRIs to accelerate the onset of therapeutic effects.
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Introduction
Selective serotonin reuptake inhibitors (SSRIs) are the most widely used antidepressants.
SSRIs bind serotonin (5-HT) transporters and block 5-HT reuptake from the synaptic cleft to
nerve terminals, resulting in prolonged stimulation of 5-HT receptors. 5-HT1A autoreceptor-
mediated feedback regulation of 5-HT release is transiently increased and then becomes
desensitized likely contributing to the initial increase in anxiety experienced by some
individuals as well as the delay of the therapeutic effects of SSRIs (Artigas et al., 2006). One
of the major problems with the use of SSRIs is that the therapeutic effects take an average
6–7 weeks of treatment (Gaynes et al., 2009). Clearly, reducing this delay with adjuvant
therapy such as estrogens could improve the clinical benefits of SSRIs.
5-HT1A receptors, including autoreceptors and postsynaptic receptors, are involved in
emotional regulation (Albert and Lemonde, 2004; Hoyer et al., 1994). Postsynaptic 5-HT1A
receptors may be directly involved in therapeutic effects of SSRIs (Millan, 2003). Both
human and rodent studies demonstrate that repeated administration of SSRIs attenuate 5-
HT1A receptor agonist-induced increase in oxytocin and adrenocorticotropic hormone
(ACTH) secretion, suggesting a desensitization of 5-HT1A receptors in the paraventricular
nucleus of the hypothalamus (PVN) (Gomez-Gil et al., 2010; Lerer et al., 1999; Lesch et al.,
1991; Li et al., 1996). Since these hormones are related to the pathogenesis of depression,
desensitization of 5-HT1A receptors in the PVN may contribute to the therapeutic effects of
SSRIs (Coryell et al., 2008; Wasserman et al., 2010). Seven to 14 days of treatment with
either the SSRI fluoxetine or paroxetine resulted in desensitization of 5-HT1A receptor
signaling in the PVN (Li et al., 1997b; Li et al., 1996; Raap et al., 1999). Although treatment
with fluoxetine and paroxetine for up to 14 days did not significantly reduce the density of
5-HT1A receptors in the PVN (Li et al., 1997a; Li et al., 1997b), the levels of Gαz protein in
the hypothalamus were reduced with 14 days of treatment with fluoxetine (Raap et al.,
1999). Adjuvant treatment that hastens alterations in the expression of components of the 5-
HT1A receptor signaling pathway could reduce the time needed to cause desensitization of
5-HT1A receptor signaling in the PVN.
Alterations in components of the 5-HT1A receptor system could underlie the changes in
hormone response with anti-depressant therapy. Studies have demonstrated that the oxytocin
and ACTH responses to 8-OH-DPAT are mediated by 5-HT1A receptors in the PVN (Bagdy,
1996; Osei-Owusu et al., 2005). 5-HT1A receptors are G-protein-coupled receptors that
couple to the Gαi/o protein family of Gα proteins. Our previous studies demonstrated that
the 5-HT1A receptors mediating the hormone responses to 8-OH-DPAT are coupled to Gαz
protein, a member of Gαi/o protein family (Serres et al., 2000). Reductions in the levels of
either functional 5-HT1A receptors or Gαz protein in the PVN could underlie the
desensitization of 5-HT1A receptor signaling as indicated by decreased oxytocin and ACTH
responses to 8-OH-DPAT. Currently, little data is available regarding the cellular location
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and post-translational modifications to Gαz proteins. Knowing the effects of SSRIs on
components of the 5-HT1A receptor signaling pathway, could have a significant impact on
the understanding of the mechanisms underlying the SSRI-induced desensitization of 5-
HT1A receptors in the PVN.
Estrogens are involved in the regulation of emotional states (Alexander et al., 2007).
Administration of estradiol, a major endogenous form of estrogen, produces desensitization
of 5-HT1A receptor signaling, suggesting that the effects of estradiol on mood regulation
may be mediated by alterations in 5-HT1A receptor signaling (Bethea et al., 2000; Mize et
al., 2003; Raap et al., 2000). Our previous studies demonstrated a partial desensitization of
5-HT1A receptor signaling in the PVN with 2 days of estradiol treatment and further noted
changes in expression of components of the 5-HT1A receptor signaling pathway in the PVN
(Garzon et al., 2011; Raap et al., 2000). In addition to the two classes of nuclear estrogen
receptors (ER), ERα and ERβ, estradiol also activates the G-protein coupled receptor,
GPR30, also known as GPER (Filardo and Thomas, 2005). Our previous studies
demonstrated that GPR30, but not ERβ, mediates the estradiol-induced desensitization of 5-
HT1A receptors in the PVN (McAllister et al., 2012; Rossi et al., 2010; Xu et al., 2009). In
addition, the detergent resistant microdomain (DRM) of plasma membrane, including lipid
rafts and calveolae, contains G-protein-coupled receptors, G-proteins and other proteins
associated with GPCR signaling, physically bringing together the components for GPCR
signaling. Thus, DRM plays a role in assembling GPCR signaling pathways and possibly
integrating the interactions among signaling pathways such as 5-HT1A receptor and GPR30
signaling pathways. Understanding the signal pathways will help us to determine the
mechanisms underlying the GPR30-mediated desensitization of 5-HT1A receptors.
A complete blockade of hormonal responses to a 5-HT1A receptor agonist requires at least 7
days of SSRI treatment (Li et al., 1996), and estradiol produces a partial desensitization after
2 days of treatment (Garzon et al., 2011). Thus, we hypothesize that combined
administration of an SSRI and estradiol accelerates the desensitization of 5-HT1A receptors
in the PVN, which is mediated by synergistic effects on alterations in components of the 5-
HT1A receptor signaling pathway. To test this hypothesis, we examined the effects of
treatment with estradiol and the SSRI fluoxetine on hormonal responses to a 5-HT1A
receptor agonist, as an index of the function of 5-HT1A receptors in the PVN. To examine
possible molecular mechanisms mediating the SSRI-and estradiol-induced alterations in the
5-HT1A receptor and GPR30 signaling pathways, we further studied the cellular location and
post-translational modifications of Gαz and GPR30, as well as the effects of EB or/and
fluoxetine on the expression of 5-HT1A receptors, Gαz protein and GPR30 in the PVN.
Methods
Drugs and reagents
Fluoxetine and 17β-estradiol -3-benzoate (EB) were purchased from Sigma (St Louis, Mo).
Fluoxetine was dissolved in saline (5 mg/ml) by heating the solution until completely
dissolved. 8-OH-DPAT was purchased from Tocris Biosciences (Ellisville, Mo) and was
dissolved in saline. N-ethymaleimide (NEM) a cysteine peptidase inhibitor, protease
inhibitor cocktail, and phosphatase inhibitor cocktail I and II were purchased from Sigma (St
Louis, MO). HRP-conjugated goat-anti-rabbit IgG and goat-anti-mouse IgG antibodies were
purchased from Jackson Immuno Research Laboratories, Inc. (West Grove, PA). The rabbit-
anti-5-HT1A receptor antibody that was kindly provided by Dr. Karie Scrogin at Loyola
University Chicago was generated to against a 24 amino acid peptide (NH2-
GTSSAPPPKKSLNGQPGSGDWRRC-OH) located in the amino acid 243–267 of rat 5-
HT1A receptors (Accession # NM_012585).
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Adult female Sprague-Dawley rats (225–250g) purchased from Harlan Laboratories
(Indianapolis, IN) were housed two per cage in a temperature-, humidity-, and light-
controlled room (12 h light/dark cycles). Food and water were available ad libitum. All
procedures were conducted in accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals and as approved by Loyola University Chicago or
the University of Kansas Institutional Animal Care and Use Committees.
Experimental procedure
Experiment 1. To determine the effects of estradiol and fluoxetine on the
desensitization of 5-HT1A receptors in the PVN—Female rats were ovariectomized
as previously described (Rossi et al., 2010). Five days after ovariectomy, rats were injected
with sesame oil (Oil) or 17β-estradiol-3-benzoate (EB) (10µg/0.4ml/kg, sc) and saline or
fluoxetine (10 mg/2 ml/kg, sc) for 7 days. Animals in the 2-day treatment groups received
oil and/or saline for 5 days and then were injected with EB and/or fluoxetine for 2 days. The
two injections (Oil/EB and saline/fluoxetine) were performed on the left and right side of the
upper back of rats, respectively. Eighteen hours after the last injection, rats were injected
with saline or the 5-HT1A receptor agonist, 8-OH-DPAT (40µg/kg, sc) and decapitated 15
min later. The trunk blood was collected into a tube containing 0.5 ml of 0.3M EDTA.
Plasma aliquots were stored at −80°C until used for plasma oxytocin and ACTH assays.
Experiment 2. To determine the mechanisms mediating the accelerating
effects of EB on fluoxetine-induced desensitization of 5-HT1A receptors in the
PVN—Since we observed that combined treatment of EB and fluoxetine for 2 days
accelerated the desensitization of 5-HT1A receptors in Experiment 1, we next examined
alterations in components of the 5-HT1A receptor signaling pathway in the PVN of rats
treated with EB and/or fluoxetine for 2 days. Ovariectomized female rats were injected with
EB (10 µg/kg, 0.4ml/kg, sc) and/or fluoxetine (10 mg/kg, sc) for 2 days as described above.
Eighteen hours after the last injection, rats were injected with saline or 8-OH-DPAT (200µg/
kg, sc) and were then decapitated 15 min after the injection. Using 200µg/kg of 8-OH-DPAT
was based on a new dose response study for 8-OH-DPAT (Creech et al., 2012). The trunk
blood was collected for plasma estradiol, oxytocin and ACTH assays. The brains were
removed and flash-frozen in dry-ice-cooled isopentane followed by freezing in dry ice for an
additional 10 min. The brains were wrapped with parafilm and aluminum foil and were
stored at −80°C until used for western blot assays. The PVN were used for immunoblot
assay to determine protein levels of 5-HT1A receptors, Gαz protein and GPR30 in response
to EB and/or fluoxetine treatment. Due to the need for larger amounts of tissue, we used rat
cortex, hippocampus and the hypothalamus without PVN for isolation of the detergent
resistant microdomain (DRM), subcellular distribution and immunoprecipitation studies.
These brain regions have a high density of 5-HT1A receptors and express estrogen receptors
including GPR30. Furthermore, their membrane location, G-protein coupling and the
regulation by agonist stimulation are similar among the brain regions. Thus, the data
observed from these brain regions should be relevant for understanding the regulation of 5-
HT1A receptor signaling in general.
Biochemical assays
Hormone assays—Plasma oxytocin and ACTH were examined using a
radioimmunoassay as previously described (Li et al., 1996; Rossi et al., 2010). The intra-
and inter-assay variances for ACTH assay were 4.2 and 14.6%, respectively. The intra- and
inter-assay variances for oxytocin assay were 5% and 9%, respectively. Plasma estradiol
concentrations were measured using an estradiol radioimmunoassay kit from Siemens
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Medical Solutions Diagnostics (Los Angeles, CA). 0.2 ml of plasma was used for the assay.
Estradiol concentrations were measured in duplicate and are presented as the mean of the
duplicates.
Isolation of detergent resistant microdomain (DRM) from cortex tissue—To
determine whether Gαz protein and GPR30 are located in the DRM, we isolated DRM from
the cortex using a protocol described by Kumari and Francesconi (Kumari and Francesconi,
2011) with minor modification. Briefly, rat cortex was homogenized with a homogenator
driven by an overheadmotor at 500 rpm for 25 strokes in 10 volume of homogenate buffer
(10 mM Tris–HCl, pH 7.4, 5 mM EDTA, 320 mM sucrose, 20mM NEM, 1:100 dilution of
protease inhibitor cocktail (Sigma) and phosphatase inhibitor II & III cocktails (Sigma)).
The homogenate was centrifuged at 800×g for 15 min at 4°C to remove the nucleus and cell
debris. The supernatant was then centrifuged at 30,000×g for 30 min at 4°C. The pellet was
resuspended in 2.2 ml of extracting buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 5 mM
EDTA, 0.5% Triton X-100 (v/v), 20mM NEM, 1:100 dilution of protease and phosphatase
inhibitor cocktails) and was then incubated for 10 min in ice (total extraction, Triton X-100
treatment). 2 ml of the Triton X-100-treated homogenate was adjusted to a final
concentration of 40% sucrose with an 80% sucrose solution in extracting buffer. The 40%
sucrose Triton X-100-treated homogenate was placed on the bottom of a 13 ml
centrifugation tube and was overlaid with 6 ml of 30% sucrose on the top. Finally, 2 ml of
5% sucrose buffer was placed on the top of 30% sucrose. The sucrose gradient was then
centrifuged at 230,000× g, 4°C for 16 hours. After the centrifugation, 1 ml fractions were
collected from top to bottom. To solubilize the membrane protein, 0.1 ml of 10% sodium
cholate was added to the fractions, which were then sonicated and shaken for one hour at
4°C. The fractions were aliquoted and stored in −80°C until use. The protein concentration
of the fractions was measured using Pierce BCA protein assay kit (Thermo Scientific Inc,
Rockford IL). Ten and 300–1,000 µg of protein were used for immunoblot and
immunoprecipitation assays, respectively.
Subcellular fractionation of rat hippocampus—To separate endoplasmic reticulum,
endosomes, Golgi, plasma membrane, ERGIC (Endoplasmic Reticulum-Golgi Intermediate
Compartment) and TGN from the hippocampal tissue, we conducted an OptiPrep
discontinuous gradient centrifugation based on the manufacture’s protocol (http://www.axis-
shield-density-gradient-media.com/organelleindexes.htm, Application 05 and 22), with
modification. The hippocampus from four rats was homogenized in 4 volumes of
homogenate buffer (0.32M sucrose, 1mM EDTA 10mM Tris-HCl pH 7.4, 20 mM NEM,
1/100 dilution of protease and phosphatase inhibitors) using a Powergen 1000 homogenizer
at speed 5, 4°C for ~10 sec. After a centrifugation at 1500× g, 4°C for 15 min, the
supernatant was used for OptiPrep discontinuous gradient centrifugation. Iodixanol
(OptiPrep, Sigma) was diluted into 7.5, 10, 12.5, 15, 20, 25 and 30% with Diluent (0.25mM
sucrose, 6mM EDTA 60mM Tris-HCl pH 7.4, 20 mM NEM, 1/100 dilution of protease and
phosphatase inhibitors). 1 ml of each solution from 7.5% to 30% was underlayed
sequentially in a 13 ml SW41 centrifuge tube. 1 ml brain homogenate supernatant was
layered on the 7.5% iodixanol solution and centrifuged at 200,000× g, 4°C for 3 hours in a
SW41 rotor. After the centrifugation, 0.5 ml fractions were collected from the top to the
bottom of the tube. The membrane proteins were then solubilized with 50 µl 10% sodium
cholate as described above.
Immunoprecipitation (IP)—IP was conducted using 300–1000 µg protein of the brain
tissue preparation or fractions in a total volume of 500 µl IP buffer (50 mM Tris, pH 7.4, 10
mM EGTA, 100 mM NaCl, 0.5% Triton X-100, containing 20 mM NEM and 1:100 dilution
of protease and phosphatase inhibitor cocktails) as previously described (Garzon et al.,
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2011). After pre-absorption of endogenous IgG, the protein was incubated in primary
antibodies (Table 1) at 4°C overnight with nuitating. To control for non-specific interactions
with the IgG antibody and agarose beads, the same amount of IgG (from the same animal
source as the antibody used for immunoprecipitation) was added into another tube
containing the same amount tissue. For an antibody control, 4 µg antibodies were added into
500 µl IP buffer. The solution was then incubated with 50µl pre-washed agarose-protein G
beads (Invitrogen) for 2 hours at 4°C with nuitating. After washing three times with 0.5 ml
IP buffer, 25 µl PAGE sample buffer (1.3×) was added and incubated at 95°C for 5 min to
elute bound proteins. The elution (~35–40µl) from each IP reaction was resolved with
PAGE to identify the proteins, as described below. Samples from SUMO1 IP were blotted
with rabbit-anti-Gαz antibody followed by goat-anti-rabbit IgG antibody. The samples from
Gαz IP were blotted with sheep-anti-SUMO1 followed by donkeyanti-sheep IgG. The same
blots were then blotted with rabbit-anti-Gαz antibody follow by goatanti-rabbit IgG light
chain (Jackson ImmunoResearch Lab Inc., West Grove, PA).
Immunoblot assays—To determine the protein levels of 5-HT1A receptors, Gαz proteins
and GPR30 in fluoxetine and/or EB treated rats, the PVN was punched from 300µm coronal
sections (2–3 sections, AP ~(−1.08) − (−2.04) mm from bregma) of the brain (Paxinos and
Watson, 2007). The 300 µm sections were placed on a slide and were kept in the cryostat
chamber. A triangle with a dorsal line between two fornices at the top of third ventricle and
two lines from ends of the dorsal line to the middle of 3rd ventricle was dissected as shown
in our previous paper (McAllister et al., 2012). The membrane fractions of the PVN were
prepared and used for immunoblot assay as described previously (Garzon et al., 2011). 5 µg
of the membrane samples were used for the immunoblot analysis. The dilutions of the
primary antibodies are listed in Table 1. To detect the loading variation, the membranes
were re-incubated with mouse-anti-β-actin.
To quantify the proteins, the IOD from each band was first normalized with its β-actin band
(target protein band/actin band). Then the percent of each sample relative to the mean of the
control samples (saline/oil) in the same blot was calculated. Each sample was measured in
three gels and the mean of the triplicates was used to represent the level of the protein (% of
saline/oil).
Transfection and recombinant adenoviral treatment—Tranfection of pcDNA4.1-5-
HT1A construct into HEK 293 and A1A1V cells was conducted using lipofactamine reagent
and lipofactamine/plus reagents, respectively. A full length rat 5-HT1A receptor sequence
(encoding 1–1269 bp (Accession No. NM_012585) was constructed into Bam HI and Eco
RI sites of pcDNA 4.1 vector. The pcDNA4.1-5HT1A or pcDNA4.1 vector was transfected
into HEK 293 and A1A1V cells according to the manufacturer’s protocols (Invitrogen,
Carlsbad, CA).
Unilateral injection of recombinant adenovirus was conducted as previously described
(McAllister et al., 2012; Rossi et al., 2010). Recombinant adenovirus containing antisense
for full length Gαz coding sequence was generated as described in our previous study (Li et
al., 2004).
Data analysis and statistics—All data were analyzed by analysis of variance
(ANOVA) using StatView (Abacus Concepts Inc., Berkeley, CA). If a significant difference
was detected, a Student-Newman-Keuls post-hoc test was used to evaluate differences
between individual groups. The data are presented as group means ± SEM of 8–14 rats in
hormone studies and 6–8 rats in immunoblot assays, unless noted otherwise.
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Treatment with EB accelerates fluoxetine-induced desensitization of 5-HT1A receptors in
the PVN
To determine whether EB can accelerate fluoxetine-induced desensitization of 5-HT1A
receptors in the PVN, we treated ovariectomized rats with EB and/or fluoxetine for 2 or 7
days. The oxytocin and ACTH responses to the 5-HT1A receptor agonist, 8-OH-DPAT were
used to assess the function of the 5-HT1A receptor signaling pathway in the PVN. Our
results (Figure 1A) show that pre-treatment with EB and/or fluoxetine did not alter the basal
level of plasma oxytocin. Administration of 8-OH-DPAT significantly increased oxytocin
secretion in the vehicle (saline/oil pre-treated) group. Treatment with EB for 2 or 7 days or
fluoxetine for 2 days partially reduced the oxytocin response to 8-OH-DPAT to a similar
level. The reduction in the oxytocin response to 8-OH-DPAT was more extensive in the rats
injected with combined EB and fluoxetine for 2 days and further reduced in rats treated with
fluoxetine or EB and fluoxetine for 7 days (two-way ANOVA: main effect for pre-treatment
F(6,121)=14.9, P<0.0001; main effect for 8-OH-DPAT challenge F(1,121)=181.3, P<0.0001,
effect for pre-treatment × 8-OH-DPAT challenge F(6,121)=15.09, P<0.0001).
Similar to the oxytocin response, pre-treatment with EB and/or fluoxetine did not alter the
basal levels of plasma ACTH. Injection with 8-OH-DPAT significantly increased ACTH
secretion in vehicle-treated rats (Figure 1B). Treatment with EB for both 2 and 7 days
produced a partial reduction in the ACTH response to 8-OH-DPAT. Treatment with
fluoxetine for 2 days did not significantly reduce 8-OH-DPAT-stimulated ACTH secretion,
whereas 7-days of fluoxetine treatment blocked the ACTH response. Furthermore, treatment
with EB and fluoxetine for both 2 days and 7 days completely blocked the ACTH response
to 8-OH-DPAT, i.e., not significantly different from the saline-challenged group (Figure 1B,
two-way ANOVA: main effect for pre-treatment F(6,102)=47.9, P<0.0001; main effect for 8-
OH-DPAT challenge F(1,102)=468.7, P<0.0001, effect for pre-treatment × 8-OH-DPAT
challenge F(6,102)=15.09, P<0.0001).
We next studied the mechanisms mediating the synergistic effects of combined treatment
with EB and fluoxetine for two days. To ensure that the results observed in the experiment 1
are repeatable and obtain more tissue from the PVN for immunoblot assays, we repeated the
2-day treatments with EB and/or fluoxetine and determined the hormone responses to 8-OH-
DPAT again. Based on a new dose response study for 8-OH-DPAT (Garzon et al., 2011), we
used 200µg/kg in the second experiment. Five days after ovariectomy, plasma estradiol
concentrations (7.49 ± 0.74 pg/ml) were reduced compared to physiological estradiol levels
(Flugge et al., 1999). Injection of EB for 2 days significantly increased estradiol levels
(125.72 ± 11.58 pg/ml) compared to oil-treated rats and were 2–3 fold higher than
physiological levels (Flugge et al., 1999). Although treatment with EB or fluoxetine for 2
days did not alter the oxytocin response to 8-OH-DPAT, EB and fluoxetine for 2 days
significantly reduced the oxytocin response to 8-OH-DPAT (saline vs 8-OH-DPAT were
2.02±0.26 vs. 51.46±4.53 in saline/oil pretreated rats; 1.67±0.22 vs. 55.44±5.49 in saline/EB
pre-treated rats; 1.61±0.21 vs. 54.6±5.71 in fluoxetine/oil pre-treated rats and 2.08±0.53 vs.
39.96±0.71 pg/ml in EB and fluoxetine pre-treated rats; threeway ANOVA showed no
significant effects for fluoxetine and EB alone, but a significant effect for 8-OH-DPAT:
F(1,42)= 697.44, P< 0.0001 and for fluoxetine × EB: F(1,42)= 5.87, P=0.02 and for fluoxetine
× EB × 8-OH-DPAT: F(1,42)= 7.0, P=0.011.
Treatment of fluoxetine and EB alters protein levels of 5-HT1A receptors
To examine alterations in the expression of 5-HT1A receptors, we first characterized the
rabbit-anti-5-HT1A receptor antibody that was kindly provided by Dr. Karie Scrogin at
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Loyola University Chicago. We transfected plasmid containing pcDNA 4.1–5-HT1A
receptors or pcDNA 4.1 vector into HEK 293 cells or A1A1V cells (a rat cortical cell line).
48 hours later, the cells were collected and lysed. The 5-HT1A receptors were detected using
the 5-HT1A receptor antibody. As shown in Figure 2A, the 5-HT1A antibody detected a ~ 42
kD band in both HEK 293 and A1A1V cells that were transfected with pcDNA 4.1–5HT1A
receptor, but not those with pcDNA 4.1 vector (control). Since 5-HT1A receptors contain
422 amino acids, the 42 kD band is the appropriate size band for the 5-HT1A receptors
without any post-translational modifications. Besides the 42 kD band, a 55 kD band was
also detected in transfected HEK 293, suggesting a post-translationally modified 5-HT1A
receptor from transfected protein. The antibody also detected several bands in both 5-HT1A
receptor-transfected and control non-transfected cells, which could be endogenous 5-HT1A
receptors in these cell lines. We previously demonstrated that A1A1v cells endogenously
express 5-HT1A receptors (Dai et al, 2008). However, in the brain tissue preparation, the
antibody detected a ~75 kD, 55 kD and several small bands, but not the 42 kD band,
suggesting that the post-translational modifications to 5-HT1A receptors in the brain tissue
are different from that in the cell lines. The majority of 5-HT1A receptors in vivo is either in
post-translationally modified forms or is degraded. Since the 55 kD band has the highest
density and is specifically located in the membrane fraction, we measured this band in the
study to determine the effects of EB and/or fluoxetine on the protein level of 5-HT1A
receptors.
In saline-challenged rats, treatment for 2 days with fluoxetine alone, but not EB or EB plus
fluoxetine, significantly increased the protein levels of 5-HT1A receptors in the PVN
membrane fraction (Figure 2B, two-way ANOVA: main effect for fluoxetine F(1,23) = 8.05,
P =0.009). On the other hand, in the rats challenged with 8-OH-DPAT, 5-HT1A receptors in
the PVN membrane were significantly reduced in the groups treated for 2 days with
fluoxetine alone and EB plus fluoxetine (Figure 2B, two-way ANOVA showed a main effect
for fluoxetine F(1,16) = 18.59, P =0.0005).
Treatment with EB, but not fluoxetine, reduces Gαz protein in the DRM of PVN membrane
To determine the membrane location of Gαz proteins, we isolated DRM in the cortex with
Triton X-100 treatment followed by sucrose gradient centrifugation. DRM fractions were
identified by flotillin 1, a marker of DRM. As figure 3A shows, the Gαz antibody detected a
~35 kD and a ~33 kD band. Interestingly, the 35 kD band was mainly located in the DRM,
whereas the 33 kD band was in the Triton X-100 soluble fractions. This result suggests that
the 35 kD Gαz proteins may be the active form of Gαz proteins, because G-protein coupled
receptors (GPCRs) are coupled with G protein in the DRMs in the plasma membrane. To
rule out the possibility of non-selective bands detected by the Gαz antibody, we unilaterally
injected recombinant adenovirus containing a Gαz antisense sequence (Gαz-antisense-Ad)
into the hypothalamus as previously described (McAllister et al., 2012; Rossi et al., 2010).
Five days after the injection, the rats were decapitated and the brain was sectioned using a
cryostat. The virus infected region in the hypothalamus and the contra-lateral region were
punched out for immunoblot assay. As shown in figure 3B, the Gαz antisense-Ad reduced
both 35 kD and 33 kD bands, suggesting that both bands are Gαz proteins.
Interestingly, acute treatment with 8-OH-DPAT for 15 min significantly increased the ratio
of the 35 to 33 kD Gαz proteins in the membrane of PVN, which resulted from a reduction
in the 33 kD Gαz proteins (Fig. 3C, one-way ANOVA: for 35/33 kD Gαz, F(1,13) =29.485,
P<0.05; for 35 kD Gαz, F(1,5) =0.59, P=0.477; for 33 kD Gαz, F(1,8) =46.35, P<0.05). On
the other hand, treatment with EB for 2 days significantly reduced the ratio of the 35/33 kD
Gαz proteins (two-way ANOVA: main effect for EB F(1,22)=15.44, P<0.05) which resulted
from a reduction of 35 kD Gαz proteins (Fig 3D, two-way ANOVA: main effect for EB
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F(1,21)=1023, P<0.05). Fluoxetine treatment for 2 days did not alter Gαz protein levels in the
membrane fraction of the PVN compared to vehicle-treated controls.
Acute treatment with 8-OH-DPAT increased sumoylation of Gαz protein in the DRM
To determine the post-translational modification of Gαz proteins, we found that Gαz protein
can be sumoylated, especially those in the DMR (Figure 3E and 3F). Using Triton X-100
treated sucrose fractions of the cortex tissue and immunoprecipitation with a
SUMO-1antibody followed by blotting with a Gαz antibody, we detected a 35kD
sumoylated Gαz protein in the DRM fractions (Fig. 3E). Conversely, using
immunoprecipitation with Gαz antibody followed by blotting with SUMO1 antibody, we
also detected a 35 kD sumoylated Gαz protein band (Fig.3F). When the blot was
subsequently examined with a Gαz protein antibody, two bands, 35 kD and 33 kD, were
detected (Fig. 3F), confirming that the band detected by the SUMO1 antibody is Gαz
protein. Treatment with 8-OH-DPAT (200 µg/kg, sc) for 15 min increased the sumoylated
Gαz protein in the cortex (Fig. 3E) and the hypothalamus without the PVN (Fig.3G, t-test:
t(9) =4.67, P<0.05).
Treatment with EB reduced the protein level of GPR30 in the membrane of PVN
To determine the membrane location of GPR30, we examined GPR30 in the Triton X-100
treated sucrose fractions of cortex membrane preparation using immunoblot. As figure 4A
shows, the majority of GPR30 (~32 kD) was located the DRM. However, a higher molecular
mass band (~47 kD) was detected in the Triton X-100 soluble fractions (Fig 4A).
In the comparison with the vehicle-treated group (saline/oil pretreated group), injection of
EB for 2 days significantly reduced GPR30 levels in the PVN membrane fraction (two-way
ANOVA showed a significant effect for EB in saline-challenged groups: (F(1,25)=6.34,
P=0.019). However, post hoc tests did not detect additional significant differences among
the groups (Figure 4B). These data suggest that treatment with EB, but not fluoxetine,
reduced GPR30 expression in the PVN membrane.
Subcellular distribution of Gαz protein and GPR30 in the rat hippocampus
Although we determined the localization of GPR30 and Gαz proteins in the DRM, the
distribution of these proteins in the subcellular organelle is still unclear. Thus, we conducted
a gradient centrifugation of rat hippocampus to separate subcellular organelle based on their
density. Consistent with the observation from Triton X-100 treated brain membrane, the 35
kD Gαz proteins were located in the plasma membrane, as marked by Na+/K+ ATPase and
flotillin-1 (Fig 5). On the other hand, the 33 kD Gαz protein was mainly co-localized with
the fractions containing cytosol and endosome markers, LDH and EEA1, respectively.
Similarly, the GPR30 (~ 32 kD) was co-localized with plasma membrane markers, Na+/K+
ATPase and flotillin-1, which is consistent with the results shown in Triton X-100 treatment
study. On the other hand, a 47 kD GPR30 protein band was co-localized with trans-Golgi
network, ER and Golgi-ER intermediate compartment markers, TGN 38, calreticulin and
LMAN-1. Furthermore, a small band was detected in these same fractions. In addition, a
~40 kD GPR30 band was detected in the cytosolic fractions (Fig 5).
Discussion
One of the challenges for improving the effectiveness of SSRIs is to identify adjuvant
treatment to hasten the onset of therapeutic effects. Desensitization of 5-HT1A receptors,
especially in the PVN, is related to the therapeutic effects of SSRIs (Gomez-Gil et al., 2010;
Polter and Li, 2010). Thus, acceleration of the desensitization of 5-HT1A receptor signaling
may hasten the therapeutic effects of these drugs. In the present study, we demonstrated that
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treatment with estradiol accelerates fluoxetine-induced desensitization of 5-HT1A receptor
signaling in the PVN. Furthermore, we identified several molecular mechanisms that could
contribute to desensitization response caused by fluoxetine, EB and the combination of both
fluoxetine and EB.
Reductions in the magnitude of hormone responses to 8-OH-DPAT indicate a
desensitization of the 5-HT1A receptor signaling in the PVN (Carrasco and Van de Kar,
2003; Van de Kar and Blair, 1999). In the present study, we used this approach to assess the
function of 5-HT1A receptors in the PVN (Fig.1). Treatment with fluoxetine or EB for 2
days produced at most a partial desensitization of 5-HT1A receptors in the PVN. Treatment
with EB for 7 days produced no further reduction in the response. However, administration
of EB and fluoxetine for 2 days produced a nearly full desensitization of 5-HT1A receptors,
suggesting a synergistic effect between EB and fluoxetine. These results are consistent with
the studies by Estrada-Camarena et al.(Estrada-Camarena et al., 2006), in which they found
that treatment with estradiol accelerated fluoxetine-induced antidepressant-like behaviors
measured by the forced swim test. The effects of EB and fluoxetine were blocked by co-
injection with a 5-HT1A receptor antagonist (Estrada-Camarena et al., 2006). These results
demonstrate that administration of EB can accelerate the anti-depressant-like effects of
SSRIs via 5-HT1A receptor signaling as measured via either behavioral or neuroendocrine
indices. Although the function of 5-HT1A receptors differ among brain regions and it is
unlikely that all of the 5-HT1A receptors in the brain will respond similarly to EB, studies
have demonstrated that treatment with EB reduces 5-HT1A receptor signalling in the
hypothalamus, hippocampus, dorsal raphe and cortex (Lu and Bethea, 2002; Mize et al.,
2003; Sanchez et al., 2011), suggesting that estradiol treatment may induce desensitization
of 5-HT1A receptors not only in the PVN, but also in other brain regions. Furthermore, as a
GPCR, the subcellular distribution, G proteins coupling and the response to agonist
stimulation of 5-HT1A receptors in different brains should be similar. Therefore, the results
observed in the present study impact our understanding estradiol-induced desensitization of
5-HT1A receptors in other brain regions.
In the present study, we found that treatment with fluoxetine alone for 2 days increased 5-
HT1A receptor protein in the PVN membrane, which was prevented by the EB plus
fluoxetine treatment. The up-regulation of 5-HT1A receptors could be a transient response to
the SSRI treatment. SSRIs block 5-HT reuptake and thus increase the 5-HT concentration in
the synaptic cleft, which stimulates 5-HT1A autoreceptors and consequently reduces firing
rate of serotonin neurons. As a result, 5-HT release is reduced, which could induce the up-
regulation of postsynaptic 5-HT1A receptors. Since the 5-HT release will be increased once
the 5-HT1A autoreceptors are desensitized, the up-regulation of 5-HT1A receptors can be
reversed. This transient increase of 5-HT1A receptors could contribute to the delayed
desensitization of 5-HT1A receptor signaling. The fluoxetine-induced up-regulation of 5-
HT1A receptors is negated by treatment with EB plus fluoxetine, likely contributing to the
more rapid desensitization. Unlike in the saline-challenged rats, the 5-HT1A receptor protein
levels were significantly reduced in rats treated with either fluoxetine alone or EB plus
fluoxetine treatment after acute 8-OH-DPAT challenge (Figure 2B). Evidence has shown
that acute stimulation of 5-HT1A receptors causes an internalization of the receptors (Fichter
et al., 2010), resulting in a reduction of 5-HT1A receptors in the membrane fraction. The
differential effects of stimulation (in 8-OH-DPAT-challenged rats) on 5-HT1A receptor
levels in the membrane fraction of the saline-pretreated rats and the rats pre-treated with
fluoxetine suggest that the 5-HT1A receptors in the fluoxetine-treated rats are more
susceptible to internalization. On the other hand, unlike the other studies that reported a
reduction in the density of 5-HT1A receptor binding sites using 3H-8-OH-DPAT binding
following treatment with EB for up to one month (Lu and Bethea, 2002; Mize et al., 2003;
Sanchez et al., 2011), we did not detect an EB-induced reduction of 5-HT1A receptor levels.
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This could be due to the immunoblot assay approach used in the present study, which
measures the protein levels of 5-HT1A receptors, including active and inactive receptors,
whereas 5-HT1A receptor agonist binding only measures the active 5-HT1A receptors or the
duration of treatment with EB.
The DRM of plasma membrane, including lipid rafts and calveolae, is a planar domain in the
membrane containing high concentrations of cholesterol and glycosphingolipid (Allen et al.,
2007; Chini and Parenti, 2004). The DRM is resistant to solubilization with non-ionic
detergent, such as Triton X-100. Although it is believed that DRMs are located in the plasma
membrane, recent studies demonstrated that DRMs are also located in other membrane
organelles, such as mitochondria, ER and Golgi (Simons and Gerl, 2010). While the DRM
plays a role in assembling GPCR signaling pathways, components in the DRM dynamically
move in and out of the DMR based on the activity of GPCR signaling. Disrupting the DRM
reduces the binding capacity of 5-HT1A receptors (Pucadyil and Chattopadhyay, 2004),
suggesting that the DRM is important in the functioning of 5-HT1A receptors.
Studies have demonstrated that several G proteins, such as Gαi1/2, Gαo, Gαq/11 and Gαs,
are located in the DRM (Allen et al., 2009; Lents et al., 2009; Sugama et al., 2007; Yuyama
et al., 2007). In the present study, we demonstrated that Gαz proteins are located in the
DRM (Fig.3A). Interestingly, we detected two forms of Gαz proteins with 35 and 33 kD
mass. The 35 kD Gαz proteins are mainly located in the DRM, whereas the 33 kD Gαz
proteins are Triton X-100 soluble (Fig.3A) and located in the cytosol and endosome (Fig.5).
These data suggest that the 35 kD Gαz proteins are the form of Gαz proteins bound to
GPCR and may be modified by palmitoylation and myristoylation as data showed that these
modifications are necessary for Gαi protein to be located in the DRM (Moffett et al., 2000).
Indeed, Gαz proteins have been shown to be palmitoylated (Tu et al., 1997). Furthermore,
we found, for the first time, that the 35 kD Gαz proteins can be sumoylated in the DRM and
the sumoylated Gαz proteins are increased after acute treatment with 8-OH-DPAT (Fig. 3).
It is possible that the sumoylation is a trigger to inactivate Gαz proteins and move them out
of the DRM.
Our present results show that acute treatment with 8-OH-DPAT significantly reduced the 33
kD Gαz proteins, which could result from increased degradation of Gαz proteins (Fig. 3C).
In contrast, treatment with EB for 2 days significantly reduced the levels of the 35 kD Gαz
proteins, but not 33 kD Gαz proteins (Fig. 3D). The 35 kD Gαz proteins are located in the
DRM, where the protein may be coupled to 5-HT1A receptors. Reduction of these Gαz
proteins may contribute to EB-induced desensitization of 5-HT1A receptors. These results
suggest that the EB-induced alterations in the Gαz proteins may be mediated by different
mechanisms from that induced by acute treatment of 8-OH-DPAT. Our previous results
showed that inhibition of mitogen-activated protein kinase/extracellular signal-regulated
kinase kinase (MEK) blocked the SSRI-induced reduction in Gαz protein and
desensitization of 5-HT1A receptors (unpublished observations). These data suggest that
activation of the MEK pathway can induce reductions in Gαz protein, which were necessary
for SSRI-induced desensitization of 5-HT1A receptor signaling in the PVN. Interestingly,
GPR30 stimulation also results in increased activity of the MEK pathway (Filardo et al.,
2000). Thus, it is possible that estradiol-induced desensitization of 5-HT1A receptors is
mediated by activation of MEK pathway through stimulation of GPR30. The increased
activity of MEK pathway could result in a reduction of Gαz protein and consequently
desensitization of 5-HT1A receptors.
Our previous studies demonstrated that EB-induced desensitization of 5-HT1A receptors is
mediated by GPR30 (Xu et al., 2009). Although our previous studies have demonstrated that
ERβ does not mediate the EB-induced desensitization of 5-HT1A receptors in the PVN, we
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cannot completely rule out the involvement of ERα in this EB-induced effect. Although
further studies are necessary to investigate the role ERα, GPR30 stimulation was both
necessary and sufficient for the desensitization response. GPR30 is a membrane-associated
estrogen receptor. A study using immunocytochemistry demonstrated that stimulation of
GPR30 with EB triggers the translocation of the receptors from the cell surface to the trans-
Golgi network, where GPR30 are degraded (Cheng et al., 2011). In the present study, we
further confirmed that the majority of unmodified GPR30 (~ 32 kD) are located in the DRM
of the plasma membrane (Fig. 4A and 5), whereas a modified GPR30 (~47 kD) is Triton
X-100 soluble (Fig 4A) and is co-localized with TGN and ER markers, TGN38 and
calreticulin, respectively (Fig 5). These data are consistent with the observation by Cheng et
al. (Cheng et al., 2011). They found that ubiquinated GPR30 are located in the TGN and
degraded in the proteasome. It is possible that the 47 kD GPR30 band detected in our study
is ubiquinated GPR30, although further confirmation is needed. Furthermore, a small band
(~15 kD) was observed in the TGN and ER fractions, suggesting that GPR30 may be
degraded in these organelles (Fig 5). We also detected a ~40 kD band with the GPR30
antibody, which is co-localized with cytosol and endosomal markers. Further studies are
required to identify this isoform of GPR30. Since the unmodified GPR30 is the active form
of the receptor, we measured this form of GPR30 in the present study. As shown in Fig 4B,
we found that treatment with EB for 2 days reduced protein levels of GPR30 in the PVN,
suggesting an EB-induced down-regulation of GPR30. This may contribute to the ability of
EB to produce only a partial desensitization of 5-HT1A receptors with 2 days of EB
treatment, but no further desensitization with longer treatments. Furthermore, selective
stimulation of GPR30 has also been shown to have anti-depressant-like effects as
demonstrated in a tail-suspension test (Dennis et al., 2009).
In conclusion, the present studies demonstrate, for the first time, that 2-day treatment with
EB accelerates fluoxetine-induced desensitization of 5-HT1A receptor signaling in the PVN.
From these studies, we found two new mechanisms by which EB could accelerate SSRI-
induced desensitization of 5-HT1A receptor signaling. First, EB prevents the fluoxetine-
induced increase in 5-HT1A receptor levels. Secondly, EB decreases Gαz proteins levels in
the DRM which may contribute to the EB-induced desensitization of 5-HT1A receptors. The
reduction in the active Gαz may result from sumoylation of Gαz and could possibly be
mediated via GPR30-induced increases in activity of the MEK pathway. Based on our
present results and the literature, we can hypothesize that SSRIs and EB-induced
desensitization of 5-HT1A receptors are mediated by different mechanisms. SSRI-induced
desensitization of 5-HT1A receptors is mediated by an increase in the 5-HT concentration in
the synaptic cleft, which further stimulates 5-HT1A receptors and consequently results in
internalization and un-coupling of 5-HT1A receptors to G-proteins. On the other hand, EB-
induced desensitization is dependent on GPR30. GPR30 couples to Gαs to increase adenylyl
cyclase activity, and, via Gβγ, it causes trans-activation of epidermal growth factor (EGF)
receptors, which leads to activation of mitogen-activated protein kinase (MAPK) and
phosphotidylinositol 3-kinase (PI3K) pathways (Filardo, 2002; Prossnitz et al., 2008). We
previously demonstrated that the desensitization of 5-HT1A receptor signaling produced by
EB was blocked by pertussis toxin (Xu et al., 2009), which suggests that the desensitization
response is mediated by GPR30 activation of Gβγ signaling rather than Gαs, since Gαs
signaling is not sensitive to pertussis toxin and Gβγ signaling is (Filardo et al., 2000; Xu et
al., 2009). Increases in the activity of the MAPK and/or PI3 kinase pathway may alter
expression and post-translational modifications of Gαi/o proteins and other members in the
5-HT1A receptor signaling pathway. As a result, G proteins and other components of the 5-
HT1A receptor signaling pathway could be removed from active sites such as DRM,
resulting in a reduction in signaling. The synergy between these mechanisms underlying
SSRI- and EB-induced desensitization of 5-HT1A receptors results in a more rapid
desensitization of 5-HT1A receptors. More studies are required to test this speculative
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hypothesis. Understanding the mechanisms underlying the desensitization of 5-HT1A
receptors will have a significant impact on development of better therapeutic approaches to
treat depression. Our results provide fundamental evidence that EB accelerates the
therapeutic effects of SSRIs on the hypothalamic-pituitary system and taken together with
the accelerated anti-depressant-like behavioral effects of EB, strongly support the use of EB
as an adjuvant for SSRI therapy.
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Figure 1. Effects of fluoxetine and/or EB treatment for 2 and 7 days on hormonal response to 8-
OH-DPAT
Plasma levels of oxytocin (A) and ACTH (B) were measured 15 min after a saline or 8-OH-
DPAT injection in ovariectomized rats pre-treated with fluoxetine and EB, alone or in
combination, for 2 or 7 days. The data are presented as the mean ± SEM (n = 8–14). *:
significantly different from saline-challenged group with same pre-treatment; #:
significantly different from 8-OH-DPAT-challenged vehicle group; &: significantly
different from 2 day pretreatment groups with same treatment. A line between groups
indicates significant difference between the groups. All of the differences were determined
by ANOVA and Student Newman-Keuls post-hoc tests. Vehicle: rats treated with saline and
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oil for 7 days; EB: rats treated with saline and EB, Flx: rats treated with fluoxetine and oil
and EB plus Flx: rats treated with EB plus fluoxetine.
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Figure 2. Effects of fluoxetine and/or EB treatment for 2 days on protein levels of 5-HT1A
receptor in the PVN membrane of saline- or 8-OH-DPAT-challenged rats
A. Characterization of 5-HT1A receptor antibody: Left panel shows that the rabbit-anti-5-
HT1A receptor antibody detected 5-HT1A receptors expressed in HEK 293 and A1A1V cells
that were transfected with pcDNA-5HT1A receptors as well as endogenously expressed 5-
HT1A receptors. Right panel shows the detection of 5-HT1A receptors in the cytosol and
membrane of rat hippocampus. B: Immunoblot assay for protein levels of 5-HT1A receptors
in the PVN membrane from fluoxetine and/or EB-treated rats challenged with saline (top)
and 8-OH-DPAT (bottom). The data are presented as the mean ± SEM (n = 6–8). *:
significantly different from saline/oil group with same challenge by Student Newman-Keuls
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post-hoc test, P < 0.05. Saline/oil: rats treated with saline and oil; Saline/EB: rats treated
with saline and EB; Flx/oil: rats treated with fluoxetine and oil and Flx/EB: rats treated with
combined fluoxetine and EB.
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Figure 3. Effects of fluoxetine and/or EB treatment for 2 days and acute 8-OH-DPATon the Gαz
protein and sumoylated Gαz in the DRM
A: Immunoblot of sucrose fractions from Triton X-100 treated cortex membrane to
determine the distribution of Gαz protein in the DRM. Fractions containing the DRM were
identified by the DRM marker, flotillin; Total: Triton X-100-treated membrane preparation
without sucrose gradient centrifugation. B: To verify that both the 35 and 33 kD bands
detected by anti-Gαz antibody are Gαz proteins, we unilaterally injected recombinant
adenovirus containing Gαz-antisense sequence (Ad-Gαz-AS) into the PVN.
Immunoblotting of Gαz protein performed using tissue from the viral injection site and its
contra-lateral side of the PVN, showed that injection of Ad-Gαz-AS reduces both 35 and 33
kD Gαz proteins. C: Effect of acute treatment with 8-OH-DPAT on the ratio of 35/33 kD
Gαz protein (left y-axis) and protein level of Gαz protein (right y-axis). The data were
presented as the mean ± SEM (n=4–5). *: significantly different from saline treated group
by Student Newman-Keuls post hoc test, P < 0.05. D: Effect of EB and/or fluoxetine
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treatment for 2 days on the ratio of 35/33 kD Gαz protein (left y-axis) and protein level of
Gαz protein (right y-axis). The data are presented as the mean ± SEM (n = 5–6). *:
significantly different from saline/oil group by Student-Newman-Keuls post-hoc test. E and
F: Sumoylation of Gαz protein is verified by imunoprecipitation with anti-SUMO1 antibody
(E) and anti-Gαz antibody (F). Flotillin 1 shown in (E) was prepared using 8-OH-DPAT-
treated fractions. IP: immunoprecipitation, IB: Immunobloting. IgG: Rabbit IgG. Input:
sample without IP. G: Sumoylated Gαz protein in the hypothalamus without PVN was
increased by acute treatment with 8-OH-DPAT. The data were normalized to sumoylated β-
actin and calculated as described in Methods. The data are presented as the mean ± SEM
(n=5–6). *: significantly different from saline treated group by t-test, P < 0.05.
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Figure 4. Effects of fluoxetine and/or EB treatment for 2 days on protein levels of active form of
GPR30 in the membrane of the PVN
A: The majority of non-modified GPR30 (~32 kD is located in the DRM; Total: Triton
X-100-treated membrane preparation without sucrose gradient centrifugation. B: Effect of
EB and/or fluoxetine treatment for 2 days on the protein level of GPR30. The data are
presented as the mean ± SEM (n = 5–6). Two-way ANOVA showed a significant difference
on the effect of EB, although no significant difference between individual groups was
detected with the Student Newman-Keuls post-hoc test.
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Figure 5. Subcellular distribution of Gαz protein and GPR30 in rat hippocampus
Immunoblots shows the co-localization of Gαz protein and GPR30 with plasma membrane
markers, Na+/K+ ATPase α1 and flotillin 1; ER marker, calreticulin; ER-Golgi intermediate
compartment marker, LMAN1 (Lectin, Mannose-binding 1, or ERGIC 53); trans-Golgi
network marker, TGM 38 (Trans-Golgi network protein2); endosome marker, EEA1(early
endosome antigen 1) and cytosol marker, LDH (lactate dehydrogenase). Mem and Cyto
indicate the total membrane fraction and cytosolic fraction of the cortex tissue prepared as
described previously (Creech et al., 2012).
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Table 1
Antibodies used for immunoprecipitation and immunoblots
Antibodies IP Immunoblot Source
Mouse-anti-SUMO-1 (D-11) 4 µg Santa Cruz #sc-5308
Rabbit-anti-SUMO-1 1:1000 Enzo #BML-PW0505
Rabbit-anti-Gαz (1–20) 4 µg 1:2000 Santa Cruz #sc-388
Rabbit-anti-5HT1A receptor 1:500 gift from Dr. Scrogin
Rabbit-anti-GPR30 1:1000 Novus, # NLS4271
Mouse-anti-Flotillin-1 1:2000 BD #610820
Mouse-anti-Na+/K+ ATPase α1 1:2000 Santa Cruz #sc-21712
Rabbit-anti-calreticulin 1:2000 Abcam #Ab4
Rabbit-anti-LMAN1 1:500 Epitomic #T3357
Rabbit-anti-TGN38 (M290)* 1:1000 Santa Cruz #sc-33784
HRP conjugated LDH 1:4000 Abcam #Ab7639-1
Goat-anti-EEA1 (C-15) 1:1000 Santa Cruz #sc-6414
Mouse-anti-β-actin (C4) 1:20,000 (30–60 min) MP #69100
Abcam: Abcam Inc. Cambridge, MA; BD: BD Biosciences San Jose, CA; Enzo: Enzo Life Sciences Inc. Farmingdale, NY; Epitomics: Epitomics
Inc. Burlingame, CA; MP: MP Biomedicals, LLC, Solon, OH; Novus: Novus Biologicals Inc., Littleton, Co; Dr. Scrogin: Karie E Scrogin at
Loyola University Chicago; Santa Cruz: Santa Cruz Biotechnology Inc., Santa Cruz, CA.
*
Wash with 2% milk in 1% Tween 20 TBS.
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